Apollomics Announces Presentations of Vebreltinib Data at ESMO 2023

FOSTER CITY, Calif., Oct. 16, 2023 -- Apollomics Inc. , a late-stage clinical biopharmaceutical company developing multiple oncology drug candidates to address difficult-to-treat and...

Related Keywords

China ,Guangzhou ,Guangdong ,Kunpeng ,Italy ,Madrid ,Spain ,United States ,Jilin ,Veneto ,Beijing ,Jin Ji Yang ,Guo Liang Yu ,Sean Leous ,Peter Vozzo ,Veneto Institute Of Oncology ,Guangdong Lung Cancer Institute ,Guangdong Academy Of Medical Sciences ,Pearl Biotechnology Co ,Securities Exchange ,Exchange Commission ,Southern Medical University ,Giulia Cerretti Veneto Institute Of Oncology ,European Society Of Medical Oncology Congress ,Apollomics Inc ,Nasdaq ,European Society ,Medical Oncology Congress ,Beijing Pearl ,Chief Executive Officer ,Preliminary Results ,Guangdong Provincial People ,Guangdong Academy ,Medical Sciences ,Veneto Institute ,Giulia Cerretti ,Mini Oral ,Beijing Pearl Biotechnology ,Securities Act ,Securities Exchange Act ,Markets ,